UCB (OTCMKTS:UCBJY) shares cross below the 50-day moving average of $41.75
The UCB SA (OTCMKTS:UCBJY – Get Rating) share price fell below its 50-day moving average during Tuesday’s session. The stock has a 50-day moving average of $41.75 and is trading as low as $37.64. UCB shares last traded at $37.71, with a volume of 69,536 shares traded in hands.
Analysts set new price targets
A number of research analysts have weighed in on the stock recently. Societe Generale cut its price target on UCB shares from €111.00 ($113.27) to €106.00 ($108.16) and set a “buy” rating for the company in a report research on Monday, June 27. Deutsche Bank Aktiengesellschaft cut its price target on UCB shares from €95.00 ($96.94) to €90.00 ($91.84) in a Tuesday, June 7 research report. UBS Group cut its price target on UCB shares from €95.00 ($96.94) to €87.00 ($88.78) and set a “neutral” rating for the company in a report by search for Monday, June 27. Berenberg Bank cut its price target on UCB shares from €122.00 ($124.49) to €120.00 ($122.45) and set a “buy” rating for the company in a report search on Friday, May 20. Finally, Morgan Stanley downgraded UCB shares from an “overweight” rating to an “equal weight” rating in a Thursday, May 19 research report. Five equity research analysts gave the stock a hold rating and four gave the stock a buy rating. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $100.75.
UCB share up 0.5%
The company’s fifty-day moving average is $41.75 and its 200-day moving average is $49.47.
UCB Company Profile
(Get a rating)
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurological and immunological diseases. The Company’s main products include Cimzia for TNF-mediated inflammatory diseases, as well as ankylosing spondylitis, axial spondylitis, Crohn’s disease, non-radiographic axial spondylitis, plaque psoriasis, psoriatic arthritis and rheumatoid arthritis. ; Vimpat, Keppra and Briviact for epilepsy; Neupro for Parkinson’s disease and restless leg syndrome; Nayzilam, a rescue nasal spray treatment for seizure clusters; and Zyrtec and Xyzal for allergies.
Get news and reviews for UCB Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for UCB and related companies with MarketBeat.com’s FREE daily email newsletter.